Herrmann K S
Arch Int Pharmacodyn Ther. 1982 Oct;259(2):180-5.
Activated platelets produce thromboxane A2, a potent vasoconstrictor, which may play an important role in pathophysiological disturbances of microcirculation. Thromboxane A2 has a very short half life and has neither been isolated nor synthesized. Hence, the recently reported stable analogue, carbocyclic thromboxane A2 (CTA2), may become an interesting tool in pharmacological research. Its vasoconstrictor potency was compared in vivo with norepinephrine, prostaglandin H2 and F2 alpha using the following method: vessels of a hamster cheek pouch preparation were exposed to a superfusion to which the respective compounds were added to give 1 ng/ml to 0.1 mg/ml final concentrations. The decrease of vessel diameters was measured microscopically. Prostaglandin H2 was found to be the most potent vasoconstrictor followed by CTA2 and norepinephrine. Prostaglandin F2 alpha was least effective. The respective maximal vasoconstrictory responses did not differ significantly.
活化血小板产生血栓素A2，一种强效血管收缩剂，其可能在微循环的病理生理紊乱中起重要作用。血栓素A2半衰期非常短，既未被分离也未被合成。因此，最近报道的稳定类似物，碳环血栓素A2（CTA2），可能成为药理学研究中一个有趣的工具。使用以下方法在体内将其血管收缩效力与去甲肾上腺素、前列腺素H2和F2α进行比较：将仓鼠颊囊制剂的血管暴露于超灌注中，向其中加入各自的化合物，使最终浓度达到1 ng/ml至0.1 mg/ml。通过显微镜测量血管直径的减小。发现前列腺素H2是最有效的血管收缩剂，其次是CTA2和去甲肾上腺素。前列腺素F2α效果最差。各自的最大血管收缩反应没有显著差异。
